Tuesday, 13 January 2026
  
Login

Australia's most trusted
source of pharma news

Tuesday, 13 January 2026
News

New Year, new pharma on the PBS

Posted 12 January 2026 AM

The first PBS listings of 2026 include the first drug listed on the PBS for a European pharma newly arrived in Australia, and an expansion of one of the biggest drugs on the market.

German-headquartered Neuraxpharm has landed its first PBS listing, with anti-CD20 monoclonal antibody Briumvi being funded on the Highly Specialised Drugs Program from 1 January for the treatment of relapsing-remitting multiple sclerosis (RRMS). It is given by an intravenous infusion and, after the initial doses, is administered twice a year, with each infusion taking about an hour.

To see the whole article, please login

Popular

New Year, new pharma on the PBS
Job moves mark start of 2026
TGA kicks off with first-in-class nod
'No deal' drugs face PBAC review
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home